Roivant Sciences Ltd. $ROIV Shares Sold by Inceptionr LLC

Inceptionr LLC trimmed its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 48.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,842 shares of the company’s stock after selling 19,568 shares during the period. Inceptionr LLC’s holdings in Roivant Sciences were worth $577,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Morgan Stanley lifted its stake in Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after buying an additional 3,254,113 shares during the last quarter. Rubric Capital Management LP grew its position in shares of Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after buying an additional 2,603,260 shares during the last quarter. State Street Corp raised its stake in Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after acquiring an additional 911,827 shares in the last quarter. Finally, UBS Group AG lifted its position in Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after acquiring an additional 15,645,836 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Citigroup boosted their price objective on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. TD Cowen increased their price objective on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Guggenheim raised their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Finally, Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.59.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the completion of the transaction, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This trade represents a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. The trade was a 11.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,855,913 shares of company stock valued at $62,649,633 in the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Roivant Sciences Price Performance

ROIV opened at $35.01 on Friday. Roivant Sciences Ltd. has a 1-year low of $10.90 and a 1-year high of $37.00. The stock has a market cap of $25.18 billion, a P/E ratio of -58.35 and a beta of 1.11. The stock’s 50 day simple moving average is $32.24 and its 200 day simple moving average is $28.62.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.